Belzupacap sarotalocan is under clinical development by Aura Biosciences and currently in Phase I for Muscle Invasive Bladder Cancer (MIBC). According to GlobalData, Phase I drugs for Muscle Invasive Bladder Cancer (MIBC) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Belzupacap sarotalocan LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Belzupacap sarotalocan overview
AU-011 is under development for the treatment of ocular melanoma (uveal and choroidal melanoma), head and neck cancer squamous cell carcinoma, non muscle invasive bladder cancer (NMIBC) (superficial bladder cancer), muscle invasive bladder cancer (MIBC), cancers of the ocular surface and other HSPG expressing cancers. It is administered as an intravitreal, suprachoroidal, intratumoral and intramural route. The therapeutic candidate is developed based on Nanosmart technology. The drug candidate is a VDC (virus like drug conjugate).
Aura Biosciences overview
Aura Biosciences is a clinical-stage biotechnology company that develop a new standard of care across multiple cancer indications and enables broad range of solid tumors using VLPs. The company is headquartered in Boston, Massachusetts, the US.
For a complete picture of Belzupacap sarotalocan’s drug-specific PTSR and LoA scores, buy the report here.